Search

everythinglearnresearchcommunity

for

Search:↓

Sorafenib after liver surgery may increase survival for some liver cancer patients.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.

The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.

A new treatment may prevent hair loss from chemotherapy by normalizing scalp cell death and reducing inflammation.

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.

EGFR inhibitors can cause unusual localized hair growth.

Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Shorter alopecia areata episodes lead to better baricitinib treatment outcomes.

Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.

Ritlecitinib effectively promotes hair regrowth in alopecia areata patients, even with extensive hair loss.

Tangent screens help detect visual field defects from vigabatrin.

Baricitinib is effective for severe alopecia areata but has some side effects.

Upadacitinib effectively treats pyoderma gangrenosum.

Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.

Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

The document concluded that there were no effective ways to prevent hair loss from chemotherapy but treatments were being explored.

Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.

Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.

Patients on dabrafenib and trametinib for melanoma often experience skin side effects.

Adriamycin and ifosfamide together work best for advanced soft tissue sarcomas.